Dianthus Therapeutics (NASDAQ:DNTH) Hits New 1-Year High – Here’s Why

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high on Wednesday . The company traded as high as $102.37 and last traded at $101.28, with a volume of 1171988 shares trading hands. The stock had previously closed at $98.64.

Wall Street Analyst Weigh In

Several research firms recently weighed in on DNTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Wells Fargo & Company assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target for the company. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Stock Performance

The firm has a fifty day simple moving average of $88.59 and a 200-day simple moving average of $73.53. The firm has a market cap of $5.21 billion, a price-to-earnings ratio of -23.09 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. Analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 87,779 shares of company stock valued at $7,985,235. Company insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the period. American Century Companies Inc. lifted its holdings in shares of Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after buying an additional 6,323 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after buying an additional 4,962 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after buying an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $27,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.